Dr John Beadle stepped down as CEO of PsiOxus in May 2021 and joins the Board as a Non-Executive Director, after leading the business since 2010. John was the founding CEO of PsiOxus after leading the acquisition of Hybrid Biosystems by Myotec Therapeutics to form PsiOxus Therapeutics Ltd. John was previously CEO of both Hybrid and Myotec. John was previously the co-founder of the DNA vaccine company PowderMed and was Chief Medical Officer and Board Director from its formation in 2004 to trade sale exit to Pfizer for over US$300 million in 2006. John has also held roles at PowderJect, Pfizer and Glaxo SmithKline where he was VP of Global Medical Operations. John was trained in Medicine at the University of Witwatersrand and received his MBA with distinction from the London Business School.